Healthcare systems and research centres around the world are beginning to adopt new gene-editing treatments for genetic blood disorders.
For example, hospitals in the Middle East recently carried out one of the region’s first treatments using CASGEVY, a CRISPR-based therapy designed to correct the faulty DNA responsible for diseases such as beta-thalassaemia.
The treatment modifies a patient’s genetic code to restore healthy haemoglobin production. Researchers believe these therapies represent a major shift toward personalised medicine, where genetic diseases can be treated at their root cause rather than only managing symptoms.
Why this matters
- Gene therapy may provide long-term cures
- Hospitals worldwide are starting to adopt the treatment
- Could transform how inherited blood disorders are treated
Source: International medical research and healthcare reports.
Leave a Reply